

**MISSISSIPPI DIVISION OF MEDICAID
DRUG UTILIZATION REVIEW (DUR) BOARD
MINUTES OF THE SEPTEMBER 20, 2018 MEETING**

DUR Board Members:	Nov 2017	Mar 2018	May 2018	Sep 2018
Lauren Bloodworth, PharmD	NA	NA	NA	✓
Beverly Bryant, MD	NA	NA	NA	✓
Rhonda Dunaway, RPh	✓	✓	✓	✓
Tanya Fitts, MD	NA	NA	NA	✓
Juanice Glaze, RPh	✓	✓	✓	✓
Alice Messer, DNP, FNP-BC	✓	✓	✓	
Ray Montalvo, MD	✓	✓	✓	
Holly Moore, PharmD		✓		✓
Janet Ricks, DO	✓	✓		✓
Dennis Smith, RPh		✓	✓	✓
James Taylor, PharmD (Chair)	✓	✓	✓	✓
Veda Vedanarayanan, MD	NA	NA	NA	
TOTAL PRESENT	9	9*	8**	9

** Only 11 members were active due to resignation resulting from move and replacements not yet approved by Governor.*

***Only 10 members were active due to resignations resulting from move and replacements not yet approved by Governor.*

Also Present:

Division of Medicaid (DOM) Staff:

Terry Kirby, RPh, CPM, Pharmacy Director; Cindy Noble, PharmD, MPH, DUR Coordinator; Gail McCorkle, RPh, Clinical Pharmacist; Chris Yount, MA, PMP, Staff Officer – Pharmacy; Jason Dees, DO, Interim Medical Director; Sue Reno, RN, Program Integrity

University of Mississippi School of Pharmacy - MS-DUR Staff:

Ben Banahan, PhD, MS-DUR Project Director; Eric Pittman, PharmD, MS-DUR Clinical Director

Conduent Staff:

Leslie Leon, PharmD, Clinical Pharmacist, Mississippi Medicaid Project;

Change Healthcare Staff:

Shannon Hardwick, RPh, CPC Pharmacist; Paige Clayton, PharmD, On-Site Clinical Pharmacist

Coordinated Care Organization Staff:

Heather Odem, PharmD, United Healthcare Community & State, Director of Pharmacy- Mississippi; Jenni Grantham, PharmD, Director of Pharmacy, Magnolia Health; Mike Todaro, PharmD, Vice President, Pharmacy Operations, Magnolia Health; Trina Stewart, PharmD, Pharmacy Manager, Molina Healthcare; Cedric Torry, PharmD, Clinical Pharmacist, Molina Healthcare

Visitors:

Phil Hecht, Abbvie; Gene Wingo, Biogen; Jason Swartz, Otsuka; John Kirby, Indivior; Dan Doyle, Trividia Health; Brad Clay, Amgen; Spencer Sullivan, MCAM; Kayla Douglas, MCAM; Sharon Pennington, MCAM; Tammuela Singleton, Tulane; Douglas Welch, Merck; Judy Clark, Consultant; Vanisha Patel, UM-SOP student; John Kenney, UM-SOP student; Anna Crider, UM-SOP student;

Call to Order:

Dr. Taylor, Chair, called the meeting to order at 2:03pm and welcomed everyone. Ms. Kirby recognized the new DUR Board members.

Old Business:

Mr. Smith moved to approve the minutes from the May 2019 DUR Board Meeting, seconded by Ms. Dunaway and unanimously approved by the DUR Board.

Resource Utilization Review:

Dr. Pittman informed the board that encounter data for both CCOs was complete for the period covered by this report. No major items noted in the reports. Dr. Noble pointed out the rank of CNS stimulants in number of claims submitted and dollars paid by Medicaid and the importance of recent recommendations by the DUR Board regarding stimulant medications.

Pharmacy Program Update:

Ms. Kirby introduced other DOM staff and DOM vendor representatives present. Ms. Kirby updated the Board on the new managed care contracts beginning October 1, 2018 that will include Molina Healthcare. Pharmacists should have received updated information to be utilized when submitting claims for the managed care organizations. On November 1, 2018 mandatory billing of 340B claims for those Medicaid providers who chose to opt in will begin.

Also beginning October 1, the new stimulant edit will go into effect. Dr. Bryant inquired about the use of stimulants in pediatric patients who do not have one of the FDA approved or compendia supported diagnoses. The Board specifically discussed the potential use of stimulants in children with autism spectrum disorder. Dr. Noble and Ms. Kirby pointed out that the electronic PA will not be able to handle this exception, but manual PA criteria will be able to address need in this situation.

Dr. Bryant made a motion that a provider education regarding the potential use of stimulants in autism spectrum disorder be developed and distributed. The motion was seconded by Ms. Glaze and unanimously approved. Dr. Bryant offered to work with DOM and MS-DUR to develop this material.

DUR Board Role/Responsibilities

Dr. Banahan provided an overview of the DUR Board and the responsibilities of DUR Board members.

Update on Action Items from Previous Board Meetings

Dr. Pittman reviewed the educational mailing statistics for ongoing and one-time mailings conducted since the last board meeting.

Sickle Cell Disease

At the May 2018 DUR Board meeting members requested to have a specialist present to the Board on sickle cell disease treatment. Drs. Spencer Sullivan, Sharon Pennington, and Tammueella Singleton provided the DUR Board an overview of current treatment standards for sickle cell disease focusing on the use of hydroxyurea, Endari, and opioids. They also addressed issues encountered by providers when treating Medicaid beneficiaries with sickle cell disease. Dr. Sullivan and his colleagues related instances where the prescribing of opioids in sickle cell patients may exceed the opioid recommendations made by the DUR Board. After a lengthy discussion, Dr. Fitts made a motion, seconded by Mr. Smith, that sickle cell be added to cancer exclusion for the opioid electronic PA edits. The motion was unanimously approved.

NEW BUSINESS

Opioid Prescribing Trends

Dr. Pittman reviewed trends related to the opioid recommendations approved by the DUR Board. Ms. Kirby updated the Board on the implementation status of edits related to DUR approved opioid recommendations. It was noted that although implementation of the opioid edits has not occurred, educational mailings pertaining to these recommendations have been ongoing. Improvement in opioid prescribing trends was noted indicating the educational mailings appear to have a positive impact.

Codeine/Tramadol Prescribing Trends in Children and Adolescents

Dr. Pittman reviewed the update on the use of codeine and tramadol products in children.

Migraines and the Introduction of Calcitonin Gene Related Peptide (CGRP) Inhibitors

Dr. Pittman provided an overview of the MS-DUR analysis of current migraine treatment in Mississippi Medicaid. Potential utilization criteria for CGRP inhibitors were presented to the Board and feedback was requested. A robust Board discussion was held focusing on issues referenced by the Institute for Clinical and Economic Review (ICER) regarding consultation for prescribing, prior medication use, presence of comorbid conditions and potential safety concerns, and initial coverage limits. After much discussion, Mr. Smith made a motion to recommend CGRP inhibitor access through a manual PA process with initial approval limited to 3 months without a requirement of prescribing or consultation by a neurologist. The motion was seconded by Dr. Bryant. The motion was approved in a 5-2 vote with Mr. Smith, Dr. Taylor, Dr. Moore, Dr. Bryant and Ms. Dunaway voting in favor of the motion. Dr. Ricks and Ms. Glaze cast dissenting votes because they supported prescribing or consultation by a neurologist. Dr. Fitts abstained from voting and Dr. Bloodworth had to leave the meeting prior to voting. The Board did recommend revisiting the matter at the first meeting in 2019.

FDA Drug Safety Updates

FDA drug safety communications from May 2018 – August 2018 were presented.

Next Meeting Information:

Proposed dates for next year were announced. Board members will be polled by email for availability for 2019 meetings.

Dr. Pittman presented Board members with the option of changing meeting times for 2019. Dr. Moore made a motion to change the times for 2019 Board meetings to 1 pm. The motion was seconded by Dr. Fitts and unanimously approved.

Dr. Taylor announced that the next meeting of the DUR Board will take place on December 6, 2018 at 2:00 p.m. He thanked everyone for their attendance and participation at the September 2018 DUR Board meeting.

The meeting adjourned at 4:30pm.

Submitted,

Eric Pittman, PharmD
Evidence-Based DUR Initiative, MS-DUR

PUBLIC MEETING NOTICES

Meeting Location: Woolfolk Building, 501 North West Street, Conference Room 145 Jackson, MS 39201

Contact Information: Pharmacy Bureau:

Chris Yount, 601-359-5253; Christopher.yount@medicaid.ms.gov, or
Jessica Tyson, 601-359-5253; jessica.Tyson@medicaid.ms.gov

Notice details:

State Agency: MS Division of Medicaid

Public Body: Drug Utilization Board (DUR) Meeting

Subject: Quarterly Meeting

Date and Time: May 31, 2018 at 2PM; Sept. 20, 2018 at 2PM; Dec. 6, 2018 at 2PM.

Description: The Mississippi Division of Medicaid's Drug Utilization Review (DUR) Board is a quality assurance body which seeks to assure appropriate drug therapy to include optimal beneficiary outcomes and appropriate education for physicians, pharmacists, and the beneficiary. The Drug Utilization Review (DUR) Board is composed of twelve participating physicians and pharmacists who are active MS Medicaid providers and in good standing with their representative organizations.

The Board reviews utilization of drug therapy and evaluates the long-term success of the treatments.

The Drug Utilization Review (DUR) Board meets quarterly.

The screenshot displays the 'PUBLIC MEETING NOTICES' website. At the top, there is a navigation bar with 'Search' and 'Login' links. Below this is a header image featuring a map of Mississippi and the text 'PUBLIC MEETING NOTICES'. The main content area is titled 'NOTICE DETAILS' and contains the following information:

- State Agency:** Division of Medicaid
- Public Body:** Division of Medicaid
- Title:** Drug Utilization Review Board
- Subject:** Quarterly Meeting
- Date and Time:** 9/20/2018 2:00:00 PM
- Description:** Mississippi Division of Medicaid quarterly Drug Utilization Review Board meeting.

On the right side of the page, there are three sections:

- MEETING LOCATION:** 501 North West Street Conf Room 145, Jackson MS 39201. Includes a 'Map this!' link.
- CONTACT INFORMATION:** Christopher Yount, 6013595253, dompharmacybureau@medicaid.ms.gov
- DOWNLOAD ATTACHMENTS:** DFA Meeting notification May Sept Dec 2018.docx, Added 1/3/2018
- SUBSCRIPTION OPTIONS:** Subscription options will send you alerts regarding future notices posted by this public body. Includes an RSS link.

A 'Back' button is located at the bottom left of the notice details section.